Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Fréderic BaronFabio EfficaceLaura CannellaMarian Stevens-KroefSergio AmadoriTheo de WitteMichael LübbertAdriano VendittiStefan SuciuPublished in: American journal of hematology (2024)
We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow (ABMT) in acute myeloid leukemia (AML) patients in first remission (CR). We observed that among patients alive and still in CR 5 years after planned auto-HSCT, approximately 10% of the patients died in the following 10 years. This stresses the need for long-term close surveillance of AML patients after auto-HSCT. Further, long-term follow-up of the trial confirms that APBSCT was comparable to ABMT in term of disease-free-survival and overall survival.
Keyphrases
- stem cells
- bone marrow
- end stage renal disease
- peripheral blood
- acute myeloid leukemia
- stem cell transplantation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- free survival
- prognostic factors
- clinical trial
- high dose
- randomized controlled trial
- public health
- rheumatoid arthritis
- adipose tissue
- phase ii
- allogeneic hematopoietic stem cell transplantation
- low dose
- skeletal muscle
- patient reported
- glycemic control
- ulcerative colitis